Please try another search
For the fiscal year ended 31 December 2021, BioInfra Life Science Inc revenues increased 37% to W1.43B. Net loss decreased 46% to W2.45B. Revenues reflect Diagnostic test service segment increase of 18% to W1.15B, Beauty equipment and cosmetics segment increase from W21.6M to W174.6M. Lower net loss reflects R & D Expense decrease of 19% to W911.2M (expense), Interest Expense decrease of 41% to W296.7M (expense).
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
---|---|---|---|
Total Revenue | 1426.44 | 1042.99 | 1874.53 |
Gross Profit | 882.55 | 459.97 | 917.4 |
Operating Income | -4321.41 | -4265.35 | -3368.98 |
Net Income | -2447.67 | -4524.43 | -3278.38 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
---|---|---|---|
Total Assets | 6870.72 | 4936.2 | 12472.81 |
Total Liabilities | 4339.18 | 6524.06 | 12760.31 |
Total Equity | 2531.54 | -1587.86 | -287.5 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
---|---|---|---|
Period Length: | 12 Months | 12 Months | 12 Months |
Cash From Operating Activities | -3412.81 | -3557.27 | -2562.23 |
Cash From Investing Activities | -3082.77 | 8082.94 | -7034.77 |
Cash From Financing Activities | 6431.1 | -4004.52 | 10056.59 |
Net Change in Cash | -63.82 | 518.22 | 458.15 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review